Adverse events in the treatment of multidrug-resistant tuberculosis: Results from the DOTS-Plus initiative

International Journal of Tuberculosis and Lung Disease

Volumn 8, Issue 11, 2004, Pages 1382-1384

  Nathanson, Eva ^a   Gupta, R ^a   Huamani, P ^b   Leimane, V ^c   Pasechnikov, A D ^d   Tupasi, T E ^e   Vink, K ^f   Jaramillo, E ^a   Espinal, M A ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b SOCIOS EN SALUD   (Peru)

^c State Ctr of TB and Lung Diseases   (Latvia)

^d PARTNERS IN HEALTH   (United States)

^e MAKATI MEDICAL CENTER   (Philippines)

^f TARTU UNIVERSITY CLINICS   (Estonia)

Author keywords

Adverse events; DOTS Plus; MDR TB; Second line drugs

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOSALICYLIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CYCLOSERINE; ETHIONAMIDE; OFLOXACIN; PROTIONAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; THIOAMIDE; TUBERCULOSTATIC AGENT;

ABDOMINAL PAIN; ALLERGIC REACTION; ANOREXIA; ARTHRALGIA; ARTICLE; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DRUG DOSE REGIMEN; ELECTROLYTE DISTURBANCE; ESTONIA; GASTRITIS; HEADACHE; HEARING DISORDER; HEPATITIS; HUMAN; HYPOTHYROIDISM; KIDNEY FAILURE; LATVIA; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; NAUSEA; NEPHROTOXICITY; PERIPHERAL NEUROPATHY; PERU; PHILIPPINES; PRIORITY JOURNAL; PSYCHOSIS; RASH; RUSSIAN FEDERATION; SEIZURE; SIDE EFFECT; SLEEP DISORDER; TINNITUS; TUBERCULOSIS; VERTIGO; VISUAL DISORDER; VOMITING;

ADULT; ANTITUBERCULAR AGENTS; DIRECTLY OBSERVED THERAPY; ESTONIA; FEMALE; HUMANS; LATVIA; MALE; MEDICATION ADHERENCE; PERU; PHILIPPINES; RETROSPECTIVE STUDIES; RUSSIA; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 10044273203     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Gupta R, Cegielski J P, Espinal M A, et al. Increasing transparency in partnerships for health: introducing the Green Light Committee. Trop Med Int Health 2002; 7: 970-976.
2. World Health Organization. Guidelines for establishing DOTS-plus pilot projects for the management of MDR-TB. In: Gupta R, Arnadottir T, eds. WHO/CDS/TB/2000.279. Geneva, Switzerland: WHO, 2000.
3. Tahaoglu K, Torun T, Sevim T, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 2001; 345: 170-174.
4. Suarez P G, Floyd K, Portocarrero J, et al. Feasibility and cost-effectiveness of a standardised second-line drugs treatment for chronic tuberculosis patients: national cohort study in Peru. Lancet 2002; 359: 1980-1989.
5. Furin J J, Mitnick C D, Shin S S, et al. Occurrence of serious adverse events in patients receiving community based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2001; 5: 648-655.
6. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348: 119-128.
7. Goble M, Iseman M D, Madsen L A, Waite D, Ackerson L, Horsburgh C R Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328: 527-532.
8. Yew W W, Chan C K, Chau C H, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin- containing regimens. Chest 2000; 117: 744-751.